STOCK TITAN

Zynerba Pharmaceuticals Inc - ZYNE STOCK NEWS

Welcome to our dedicated news page for Zynerba Pharmaceuticals (Ticker: ZYNE), a resource for investors and traders seeking the latest updates and insights on Zynerba Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zynerba Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zynerba Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.64%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
none
Zynerba Pharmaceuticals Inc

Nasdaq:ZYNE

ZYNE Rankings

ZYNE Stock Data

70.12M
35.45M
6.07%
12.13%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Devon

About ZYNE

at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.